Literature DB >> 17163234

Safety of oral ibandronate in the treatment of bone metastases from breast cancer : long-term follow-up experience.

Sue-Anne McLachlan1, David Cameron, Robin Murray, Debu Tripathy, Bengt Bergström.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17163234     DOI： 10.2165/00044011-200626010-00006

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  22 in total

1.  Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.

Authors:  S M Ali; F J Esteva; G Hortobagyi; H Harvey; J Seaman; R Knight; L Costa; A Lipton
Journal:  J Clin Oncol       Date:  2001-07-15       Impact factor: 44.544

2.  Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.

Authors:  T Yoneda; A Sasaki; C Dunstan; P J Williams; F Bauss; Y A De Clerck; G R Mundy
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

3.  Patient preferences for oral versus intravenous palliative chemotherapy.

Authors:  G Liu; E Franssen; M I Fitch; E Warner
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

4.  Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.

Authors:  Trevor Powles; Sandy Paterson; John A Kanis; Eugene McCloskey; Sue Ashley; Alwynne Tidy; Kirsi Rosenqvist; Ian Smith; Lars Ottestad; Sandra Legault; Marjo Pajunen; Auli Nevantaus; Esa Männistö; Anne Suovuori; Sari Atula; Jaakko Nevalainen; Liisa Pylkkänen
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

Review 5.  Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity.

Authors:  Debasish Banerjee; Arif Asif; Liliane Striker; Richard A Preston; Jacques J Bourgoignie; David Roth
Journal:  Am J Kidney Dis       Date:  2003-05       Impact factor: 8.860

6.  Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.

Authors:  A H Paterson; T J Powles; J A Kanis; E McCloskey; J Hanson; S Ashley
Journal:  J Clin Oncol       Date:  1993-01       Impact factor: 44.544

7.  Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study.

Authors:  A G Robertson; N S Reed; S H Ralston
Journal:  J Clin Oncol       Date:  1995-09       Impact factor: 44.544

8.  Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer.

Authors:  Jean-Jacques Body; Ingo J Diel; Richard Bell; Martin Pecherstorfer; Michail R Lichinitser; Alexander F Lazarev; Debu Tripathy; Bengt Bergström
Journal:  Pain       Date:  2004-10       Impact factor: 6.961

9.  Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.

Authors:  J-J Body; I J Diel; M R Lichinitser; E D Kreuser; W Dornoff; V A Gorbunova; M Budde; B Bergström
Journal:  Ann Oncol       Date:  2003-09       Impact factor: 32.976

Review 10.  Oral cancer treatment: developments in chemotherapy and beyond.

Authors:  V J O'Neill; C J Twelves
Journal:  Br J Cancer       Date:  2002-10-21       Impact factor: 7.640
View more
  6 in total

Review 1.  Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer.

Authors:  Paul L McCormack; Greg L Plosker
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  National consensus in China on diagnosis and treatment of patients with advanced breast cancer.

Authors:  Binghe Xu; Xichun Hu; Zefei Jiang; Huiping Li; Jiayi Chen; Shude Cui; Qing Li; Ning Liao; Donggeng Liu; Jian Liu; Jinsong Lu; Kunwei Shen; Tao Sun; Yuee Teng; Zhongsheng Tong; Shulian Wang; Xiang Wang; Xiaojia Wang; Yongsheng Wang; Jiong Wu; Peng Yuan; Pin Zhang; Qingyuan Zhang; Hong Zheng; Da Pang; Guosheng Ren; Zhimin Shao; Zhenzhou Shen; Erwei Song; Santai Song
Journal:  Ann Transl Med       Date:  2015-10

3.  Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials.

Authors:  Chun-Jing Geng; Qian Liang; Jian-Hong Zhong; Min Zhu; Fan-Ying Meng; Ning Wu; Rui Liang; Bin-Yi Yuan
Journal:  BMJ Open       Date:  2015-06-02       Impact factor: 2.692

Review 4.  Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature.

Authors:  Ning Jia; Fionnuala C Cormack; Bin Xie; Zita Shiue; Behzad Najafian; Julie R Gralow
Journal:  BMC Cancer       Date:  2015-07-22       Impact factor: 4.430

5.  The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: a systematic review and meta-analysis.

Authors:  Yan-Li Yang; Zi-Jian Xiang; Jing-Hua Yang; Wen-Jie Wang; Ruo-Lan Xiang
Journal:  Ther Adv Med Oncol       Date:  2019-06-09       Impact factor: 8.168

6.  Use of ibandronate in the prevention of skeletal events in metastatic breast cancer.

Authors:  Bianca Devitt; Sue-Anne McLachlan
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.